Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||ONO-7475 + Venetoclax|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ONO-7475||ONO7475||AXL Inhibitor 29 FLT3 Inhibitor 62 MERTK Inhibitor 13 TYRO3 Inhibitor 8||ONO-7475 inhibits AXL, MERTK, FLT3, and TYRO3, potentially leading to reduced growth and increased apoptosis of tumor cells (PMID: 28912176, PMID: 30501104, PMID: 31953310).|
|Venetoclax||Venclexta||ABT-199|RG7601|GDC-0199|ABT119|Venclyxto||BCL2 inhibitor 26||Venclexta (venetoclax) is a BH3-mimetic that binds to and inhibits BCL2, resulting in increased tumor cell apoptosis (PMID: 26589495, PMID: 25048785). Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination with chemotherapy in patients 75 years old or older with newly-diagnosed acute myeloid leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 exon 14 ins||acute myeloid leukemia||sensitive||ONO-7475 + Venetoclax||Preclinical - Pdx & cell culture||Actionable||In a preclinical study, the combination of ONO-7475 and Venclexta (venetoclax) synergistically inhibited cell viability and induced apoptosis in acute myeloid leukemia cell lines harboring a FLT3-ITD mutation in culture, and reduced leukemia burden and prolonged overall survival in patient-derived xenograft (PDX) and cell line xenograft models with increased efficacy over either agent alone (PMID: 34732043).||34732043|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|